School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
J Ethnopharmacol. 2024 Jun 12;327:118019. doi: 10.1016/j.jep.2024.118019. Epub 2024 Mar 11.
Clinopodium chinense Kuntze (CC) and Clinopodium polycephalum (Vaniot) C. Y. Wu & S. J. Hsuan (CP) are both included in the Pharmacopoeia of the People's Republic of China (edition 2020) as the legitimate source of "Duan Xue Liu" (DXL), which is a crucial traditional Chinese medicine used as a clinical remedy for bleeding diseases. However, the differences in plant endogenous metabolites and bioactivities between CC and CP are still unclear.
This study aims to provide a scientific basis to investigate the differences between CC and CP ensuring the efficient and safe use of DXL.
A multidimensional strategy including plant metabolomics, digital reference standard (DRS) analyzer, and biological activities assay was creatively constructed for the characterization, distinction, and quality control of CC and CP.
There were apparent differences in the metabolites between CC and CP. 7 compounds contributing to the differences were successfully identified. On that basis, linear calibration using two reference substances (LCTRS) methods was proved as a more accurate and specific quality analysis method for CC and CP. In addition, bioactivity assays showed that both CC and CP exhibited obvious hemostatic activity, while CC showed greater potential to resist inflammation and free radicals.
In summary, it was the first time to investigate the chemical constituents and bioactivities differences between CC and CP with the help of plant metabolomics, DRS study, and biological activity assays. These two plants were significantly separated in the integrated analysis, suggesting that we should pay attention to the distinction to prevent unexpected risks caused by medicinal materials.
荆芥属植物荆芥（CC）和荆芥属植物多苞荆芥（CP）均被收录于《中华人民共和国药典》（2020 年版）中，作为“断血流”的合法来源，“断血流”是一种重要的中药，用于治疗出血性疾病。然而，CC 和 CP 之间的植物内源性代谢物和生物活性差异尚不清楚。
本研究旨在为调查 CC 和 CP 之间的差异提供科学依据，以确保“断血流”的高效和安全使用。
构建了包括植物代谢组学、数字参考标准（DRS）分析仪和生物活性测定在内的多维策略，用于 CC 和 CP 的特征描述、区分和质量控制。
CC 和 CP 之间的代谢物存在明显差异。成功鉴定出 7 种导致差异的化合物。在此基础上，使用两种对照品（LCTRS）方法的线性校准被证明是一种更准确和更具特异性的 CC 和 CP 质量分析方法。此外，生物活性测定表明，CC 和 CP 均表现出明显的止血活性，而 CC 表现出更大的抗炎和抵抗自由基的潜力。
总之，这是首次借助植物代谢组学、DRS 研究和生物活性测定来研究 CC 和 CP 之间的化学成分和生物活性差异。这两种植物在综合分析中明显分离，这表明我们应该注意区分，以防止因药材引起的意外风险。
